Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trialMarket Watch • 09/09/24
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By HalfBenzinga • 09/09/24
Merck & Co., Inc. (MRK) CEO Rob Davis presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/06/24
Merck Starts Late-Stage Study on Recently Acquired Ophthalmology DrugZacks Investment Research • 09/05/24
Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial CarcinomaZacks Investment Research • 09/04/24
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024Business Wire • 09/04/24
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular EdemaBusiness Wire • 09/04/24
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall StreetBenzinga • 09/03/24
European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in AdultsBusiness Wire • 09/03/24
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing DataZacks Investment Research • 08/30/24
Merck Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)Business Wire • 08/29/24
Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceBusiness Wire • 08/29/24